{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T17:46:53Z","timestamp":1772300813478,"version":"3.50.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1004304"],"award-info":[{"award-number":["2022YFA1004304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82322067"],"award-info":[{"award-number":["82322067"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172991"],"award-info":[{"award-number":["82172991"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Research Program for Higher Education in Jiangsu Province","award":["21KJB320015"],"award-info":[{"award-number":["21KJB320015"]}]},{"name":"Shanghai Health Commission","award":["2019SY072"],"award-info":[{"award-number":["2019SY072"]}]},{"name":"Shanghai Pulmonary Hospital Research Fund","award":["FK18001"],"award-info":[{"award-number":["FK18001"]}]},{"name":"Shanghai Pulmonary Hospital Research Fund","award":["FKGG1805"],"award-info":[{"award-number":["FKGG1805"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As key oncogenic drivers in non-small-cell lung cancer (NSCLC), various mutations in the epidermal growth factor receptor (EGFR) with variable drug sensitivities have been a major obstacle for precision medicine. To achieve clinical-level drug recommendations, a platform for clinical patient case retrieval and reliable drug sensitivity prediction is highly expected. Therefore, we built a database, D3EGFRdb, with the clinicopathologic characteristics and drug responses of 1339 patients with EGFR mutations via literature mining. On the basis of D3EGFRdb, we developed a deep learning-based prediction model, D3EGFRAI, for drug sensitivity prediction of new EGFR mutation-driven NSCLC. Model validations of D3EGFRAI showed a prediction accuracy of 0.81 and 0.85 for patients from D3EGFRdb and our hospitals, respectively. Furthermore, mutation scanning of the crucial residues inside drug-binding pockets, which may occur in the future, was performed to explore their drug sensitivity changes. D3EGFR is the first platform to achieve clinical-level drug response prediction of all approved small molecule drugs for EGFR mutation-driven lung cancer and is freely accessible at https:\/\/www.d3pharma.com\/D3EGFR\/index.php.<\/jats:p>","DOI":"10.1093\/bib\/bbae121","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T02:43:50Z","timestamp":1711853030000},"source":"Crossref","is-referenced-by-count":7,"title":["D3EGFR: a webserver for deep learning-guided drug sensitivity prediction and drug response information retrieval for EGFR mutation-driven lung cancer"],"prefix":"10.1093","volume":"25","author":[{"given":"Yulong","family":"Shi","sequence":"first","affiliation":[{"name":"State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China"},{"name":"School of Pharmacy, University of Chinese Academy of Sciences , Beijing 100049 , China"}]},{"given":"Chongwu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Shanghai Pulmonary Hospital, , Shanghai 200433 , China"},{"name":"Tongji University School of Medicine , Shanghai Pulmonary Hospital, , Shanghai 200433 , China"}]},{"given":"Xinben","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China"},{"name":"School of Pharmacy, University of Chinese Academy of Sciences , Beijing 100049 , China"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[{"name":"Key Laboratory of Human Functional Genomics of Jiangsu Province , Department of Biochemistry and Molecular Biology, , Nanjing 211166 , China"},{"name":"Nanjing Medical University , Department of Biochemistry and Molecular Biology, , Nanjing 211166 , China"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Computer Science and Technology, East China Normal University , Shanghai 200062 , China"}]},{"given":"Leilei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Shanghai Pulmonary Hospital, , Shanghai 200433 , China"},{"name":"Tongji University School of Medicine , Shanghai Pulmonary Hospital, , Shanghai 200433 , China"}]},{"given":"Ying","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pathology, the First Affiliated Hospital of Nanjing Medical University , Nanjing 210029 , China"}]},{"given":"Dong","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery , Shanghai Pulmonary Hospital, , Shanghai 200433 , China"},{"name":"Tongji University School of Medicine , Shanghai Pulmonary Hospital, , Shanghai 200433 , China"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-8473","authenticated-orcid":false,"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China"},{"name":"School of Pharmacy, University of Chinese Academy of Sciences , Beijing 100049 , China"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China"},{"name":"School of Pharmacy, University of Chinese Academy of Sciences , Beijing 100049 , China"}]}],"member":"286","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"2024033102434113700_ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024033102434113700_ref2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2024033102434113700_ref3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2024033102434113700_ref4","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Kosaka","year":"2004","journal-title":"Cancer Res"},{"key":"2024033102434113700_ref5","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"2024033102434113700_ref6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2024033102434113700_ref7","doi-asserted-by":"crossref","first-page":"E3595","DOI":"10.1073\/pnas.1220050110","article-title":"Mechanism for activation of mutated epidermal growth factor receptors in lung cancer","volume":"110","author":"Red Brewer","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024033102434113700_ref8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/0284186X.2017.1404634","article-title":"A systematic review of targeted agents for non-small cell lung cancer","volume":"57","author":"Vestergaard","year":"2018","journal-title":"Acta Oncol"},{"key":"2024033102434113700_ref9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"2024033102434113700_ref10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"2024033102434113700_ref11","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"2024033102434113700_ref12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"2024033102434113700_ref13","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2024033102434113700_ref14","doi-asserted-by":"crossref","first-page":"eaan6566","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci Transl Med"},{"key":"2024033102434113700_ref15","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"2024033102434113700_ref16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2017.11.005","article-title":"A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer","volume":"114","author":"Tu","year":"2017","journal-title":"Lung Cancer"},{"key":"2024033102434113700_ref17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jtho.2016.11.2225","article-title":"EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced Asian NSCLC patients","volume":"12","author":"Sutiman","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024033102434113700_ref18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","article-title":"First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study","volume":"2","author":"Park","year":"2016","journal-title":"JAMA Oncol"},{"key":"2024033102434113700_ref19","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/annonc\/mdx017","article-title":"Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA","volume":"28","author":"Remon","year":"2017","journal-title":"Ann Oncol"},{"key":"2024033102434113700_ref20","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.jtho.2020.06.018","article-title":"Osimertinib improves overall survival in patients with EGFR-mutated NSCLC with leptomeningeal metastases regardless of T790M mutational status","volume":"15","author":"Lee","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024033102434113700_ref21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2024033102434113700_ref22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cancergen.2017.04.006","article-title":"The JAX clinical knowledgebase: a valuable resource for identifying evidence related to complex molecular signatures in different types of cancer","volume":"214-215","author":"Patterson","year":"2017","journal-title":"Cancer Genet"},{"key":"2024033102434113700_ref23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"key":"2024033102434113700_ref24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jamia\/ocw148","article-title":"The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations","volume":"24","author":"Huang","year":"2017","journal-title":"J Am Med Inform Assoc"},{"key":"2024033102434113700_ref25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","article-title":"The COSMIC (catalogue of somatic mutations in cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br J Cancer"},{"key":"2024033102434113700_ref26","article-title":"OncoKB: a precision oncology knowledge base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2024033102434113700_ref27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S1470-2045(12)70312-1","article-title":"My cancer genome: a unified genomics and clinical trial portal","volume":"13","author":"Swanton","year":"2012","journal-title":"Lancet Oncol"},{"key":"2024033102434113700_ref28","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-04-1981","article-title":"Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer","volume":"11","author":"Chou","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2024033102434113700_ref29","first-page":"1595","article-title":"EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer","volume":"8","author":"Fang","year":"2014","journal-title":"Drug Des Dev Ther"},{"key":"2024033102434113700_ref30","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","article-title":"Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib","volume":"23","author":"Han","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024033102434113700_ref31","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1073\/pnas.1819430116","article-title":"Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations","volume":"116","author":"Ikemura","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024033102434113700_ref32","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1038\/srep02855","article-title":"Personalized prediction of EGFR mutation-induced drug resistance in lung cancer","volume":"3","author":"Wang","year":"2013","journal-title":"Sci Rep"},{"key":"2024033102434113700_ref33","doi-asserted-by":"crossref","first-page":"i821","DOI":"10.1093\/bioinformatics\/bty593","article-title":"DeepDTA: deep drug-target binding affinity prediction","volume":"34","author":"\u00d6zt\u00fcrk","year":"2018","journal-title":"Bioinformatics"},{"key":"2024033102434113700_ref34","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac147","article-title":"D3AI-CoV: a deep learning platform for predicting drug targets and for virtual screening against COVID-19","volume":"23","author":"Yang","year":"2022","journal-title":"Brief Bioinform"},{"key":"2024033102434113700_ref35","doi-asserted-by":"crossref","first-page":"35D","DOI":"10.1093\/nar\/gkh073","article-title":"Database resources of the National Center for biotechnology information: update","volume":"32","author":"Wheeler","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"2024033102434113700_ref36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"2024033102434113700_ref37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2024033102434113700_ref38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2024033102434113700_ref39","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: methods and applications","volume":"3","author":"Kitchen","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2024033102434113700_ref40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"2024033102434113700_ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpbi.3","article-title":"Comparative protein structure modeling using MODELLER","volume":"54","author":"Webb","year":"2016","journal-title":"Curr Protoc Bioinformatics"},{"key":"2024033102434113700_ref42","doi-asserted-by":"crossref","first-page":"W665","DOI":"10.1093\/nar\/gkh381","article-title":"PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations","volume":"32","author":"Dolinsky","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"2024033102434113700_ref43","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/ci300604z","article-title":"Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise","volume":"53","author":"Koes","year":"2013","journal-title":"J Chem Inf Model"},{"key":"2024033102434113700_ref44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"2024033102434113700_ref45","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"2024033102434113700_ref46","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1093\/bioinformatics\/btaa1005","article-title":"DeepPurpose: a deep learning library for drug-target interaction prediction","volume":"36","author":"Huang","year":"2021","journal-title":"Bioinformatics"},{"key":"2024033102434113700_ref47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","article-title":"Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer","volume":"88","author":"Takeda","year":"2015","journal-title":"Lung Cancer"},{"key":"2024033102434113700_ref48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/annonc\/mdv593","article-title":"Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials","volume":"27","author":"Ramalingam","year":"2016","journal-title":"Ann Oncol"},{"key":"2024033102434113700_ref49","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann Oncol"},{"key":"2024033102434113700_ref50","doi-asserted-by":"crossref","first-page":"e95897","DOI":"10.1371\/journal.pone.0095897","article-title":"Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study","volume":"9","author":"Chen","year":"2014","journal-title":"PloS One"},{"key":"2024033102434113700_ref51","doi-asserted-by":"crossref","first-page":"D464","DOI":"10.1093\/nar\/gky1004","article-title":"RCSB protein data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy","volume":"47","author":"Burley","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2024033102434113700_ref52","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024033102434113700_ref53","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"key":"2024033102434113700_ref54","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12885-019-5604-6","article-title":"The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report","volume":"19","author":"Del Re","year":"2019","journal-title":"BMC Cancer"},{"key":"2024033102434113700_ref55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2741\/3607","article-title":"EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma","volume":"15","author":"Kaneko","year":"2010","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2024033102434113700_ref56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-09-1660","article-title":"Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non\u2013small cell lung cancer","volume":"16","author":"Dahabreh","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2024033102434113700_ref57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12859-018-2093-6","article-title":"Prediction of sensitivity to gefitinib\/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis","volume":"19","author":"Zou","year":"2018","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"2024033102434113700_ref58","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1039\/C6MB00038J","article-title":"Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer","volume":"12","author":"Wang","year":"2016","journal-title":"Mol Biosyst"},{"issue":"S1","key":"2024033102434113700_ref59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12920-018-0460-9","article-title":"Predicting drug response of tumors from integrated genomic profiles by deep neural networks","volume":"12","author":"Chiu","year":"2019","journal-title":"BMC Med Genomics"},{"issue":"5","key":"2024033102434113700_ref60","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1109\/TCBB.2016.2568184","article-title":"An eigen-binding site based method for the analysis of anti-EGFR drug resistance in lung cancer treatment","volume":"14","author":"Ma","year":"2016","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/3\/bbae121\/57108909\/bbae121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/3\/bbae121\/57108909\/bbae121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T02:44:28Z","timestamp":1711853068000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbae121\/7636761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbae121","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,3,27]]},"article-number":"bbae121"}}